238 related articles for article (PubMed ID: 15632910)
1. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells.
Rossi MJ; Sundararaj K; Koybasi S; Phillips MS; Szulc ZM; Bielawska A; Day TA; Obeid LM; Hannun YA; Ogretmen B
Otolaryngol Head Neck Surg; 2005 Jan; 132(1):55-62. PubMed ID: 15632910
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.
Senkal CE; Ponnusamy S; Rossi MJ; Sundararaj K; Szulc Z; Bielawski J; Bielawska A; Meyer M; Cobanoglu B; Koybasi S; Sinha D; Day TA; Obeid LM; Hannun YA; Ogretmen B
J Pharmacol Exp Ther; 2006 Jun; 317(3):1188-99. PubMed ID: 16510697
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.
Wu Y; Palad AJ; Wasilenko WJ; Blackmore PF; Pincus WA; Schechter GL; Spoonster JR; Kohn EC; Somers KD
Clin Cancer Res; 1997 Nov; 3(11):1915-21. PubMed ID: 9815580
[TBL] [Abstract][Full Text] [Related]
4. Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in Vitro.
Erjala K; Pulkkinen J; Kulmala J; Alanen K; Grenman R
Anticancer Res; 2002; 22(6A):3135-42. PubMed ID: 12530056
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
6. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.
Hambek M; Werner C; Baghi M; Gstöttner W; Knecht R
Anticancer Res; 2006; 26(2A):1091-5. PubMed ID: 16619511
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
[TBL] [Abstract][Full Text] [Related]
9. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.
Junttila MR; Ala-Aho R; Jokilehto T; Peltonen J; Kallajoki M; Grenman R; Jaakkola P; Westermarck J; Kähäri VM
Oncogene; 2007 Aug; 26(36):5267-79. PubMed ID: 17334397
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells.
Krishna S; Brown N; Faller DV; Spanjaard RA
Laryngoscope; 2002 Apr; 112(4):645-50. PubMed ID: 12150517
[TBL] [Abstract][Full Text] [Related]
11. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
12. [The effect of telomerase inhibitors on oral squamous carcinoma cells].
Yang Z; Chen W; Zhang Q
Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Jun; 21(3):231-4. PubMed ID: 12898773
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo.
Chmura SJ; Dolan ME; Cha A; Mauceri HJ; Kufe DW; Weichselbaum RR
Clin Cancer Res; 2000 Feb; 6(2):737-42. PubMed ID: 10690561
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues.
Mao L; El-Naggar AK; Fan YH; Lee JS; Lippman SM; Kayser S; Lotan R; Hong WK
Cancer Res; 1996 Dec; 56(24):5600-4. PubMed ID: 8971162
[TBL] [Abstract][Full Text] [Related]
15. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
Yin X; Zhang H; Burrows F; Zhang L; Shores CG
Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
[TBL] [Abstract][Full Text] [Related]
16. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Verheul HM; Qian DZ; Carducci MA; Pili R
Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
[TBL] [Abstract][Full Text] [Related]
17. Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma.
Liao CT; Tung-Chieh Chang J; Wang HM; Chen IH; Lin CY; Chen TM; Hsieh LL; Cheng AJ
Head Neck; 2004 Jun; 26(6):504-12. PubMed ID: 15162351
[TBL] [Abstract][Full Text] [Related]
18. Amplification of cancer cell apoptosis in photodynamic therapy-treated tumors by adjuvant ceramide analog LCL29.
Korbelik M; Zhang W; Separovic D
Lasers Surg Med; 2011 Sep; 43(7):614-20. PubMed ID: 22057489
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of telomerase activation and telomere length in head and neck cancer.
Patel MM; Parekh LJ; Jha FP; Sainger RN; Patel JB; Patel DD; Shah PM; Patel PS
Head Neck; 2002 Dec; 24(12):1060-7. PubMed ID: 12454944
[TBL] [Abstract][Full Text] [Related]
20. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma.
Hoa M; Davis SL; Ames SJ; Spanjaard RA
Cancer Res; 2002 Dec; 62(24):7154-6. PubMed ID: 12499248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]